Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 4
2005 9
2006 8
2007 5
2008 3
2009 3
2010 1
2011 1
2013 2
2019 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.
Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, Shui A, McCabe CH, Braunwald E; PROVE IT-TIMI 22 Investigators. Scirica BM, et al. J Am Coll Cardiol. 2006 Jun 6;47(11):2326-31. doi: 10.1016/j.jacc.2006.03.034. Epub 2006 May 4. J Am Coll Cardiol. 2006. PMID: 16750703 Free article.
OBJECTIVES: We aimed to determine whether intensive statin therapy reduces hospitalization for heart failure (HF) in high-risk patients. ...METHODS: The Pravastatin or Atorvastatin Evaluation and Infection Trial-Thrombolysis In Myocardial Infarction 22 (PROVE …
OBJECTIVES: We aimed to determine whether intensive statin therapy reduces hospitalization for heart failure (HF) in high-risk patien …
Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.
Truong QA, Murphy SA, McCabe CH, Armani A, Cannon CP; TIMI Study Group. Truong QA, et al. Circ Cardiovasc Qual Outcomes. 2011 May;4(3):328-36. doi: 10.1161/CIRCOUTCOMES.110.957720. Epub 2011 Apr 12. Circ Cardiovasc Qual Outcomes. 2011. PMID: 21487089 Free PMC article. Clinical Trial.
METHODS AND RESULTS: In the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial, 911 (21.9%) women and 3251 (78.1%) men were randomized to intensive statin (atorvastatin …
METHODS AND RESULTS: In the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 ( …
Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials.
Salam AM. Salam AM. Expert Opin Investig Drugs. 2004 Jun;13(6):707-13. doi: 10.1517/13543784.13.6.707. Expert Opin Investig Drugs. 2004. PMID: 15174957 Review.
Two recently published related studies addressed this question by comparing intensive lipid lowering with atorvastatin (Lipitor, Pfizer) 80 mg/day with a moderate lipid-lowering regimen of pravastatin (Pravachol, Bristol-Myers Squibb) 40 mg/day. ...The second study, …
Two recently published related studies addressed this question by comparing intensive lipid lowering with atorvastatin (Lipito …
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Murphy SA, et al. J Am Coll Cardiol. 2009 Dec 15;54(25):2358-62. doi: 10.1016/j.jacc.2009.10.005. J Am Coll Cardiol. 2009. PMID: 20082923 Free article. Clinical Trial.
BACKGROUND: In the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial, more intensive lipid lowering with high-dose atorvastatin reduced the first occurrence of the prim …
BACKGROUND: In the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myoca …
Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CP; TIMI Study Group. Gibson CM, et al. J Am Coll Cardiol. 2009 Dec 8;54(24):2290-5. doi: 10.1016/j.jacc.2009.09.010. J Am Coll Cardiol. 2009. PMID: 19958964 Free article. Clinical Trial.
METHODS: Outcomes were compared in 2,868 patients who underwent PCI for ACS just prior to enrollment in the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial, which randomized patien …
METHODS: Outcomes were compared in 2,868 patients who underwent PCI for ACS just prior to enrollment in the PROVE IT-TIMI 22 ( …
Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
Rouleau J. Rouleau J. Am J Med. 2005 Dec;118 Suppl 12A:28-35. doi: 10.1016/j.amjmed.2005.09.014. Am J Med. 2005. PMID: 16356805
The aim of the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial was to determine whether intensive low-density lipoprotein (LDL)-cholesterol lowering to a level of approximat …
The aim of the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE …
Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
Giraldez RR, Giugliano RP, Mohanavelu S, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Giraldez RR, et al. J Am Coll Cardiol. 2008 Sep 9;52(11):914-20. doi: 10.1016/j.jacc.2008.05.046. J Am Coll Cardiol. 2008. PMID: 18772061 Free article. Clinical Trial.
CONCLUSIONS: A progressive reduction in the benefit of intensive LLT with atorvastatin 80 mg over pravastatin 40 mg occurred in statin-naive ACS patients as baseline LDL-C declined. (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in …
CONCLUSIONS: A progressive reduction in the benefit of intensive LLT with atorvastatin 80 mg over pravastatin 40 mg occurred i …
Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial.
Ahmed S, Cannon CP, Murphy SA, Braunwald E. Ahmed S, et al. Eur Heart J. 2006 Oct;27(19):2323-9. doi: 10.1093/eurheartj/ehl220. Epub 2006 Sep 5. Eur Heart J. 2006. PMID: 16954134 Clinical Trial.
AIMS: The impact of intensive lipid lowering therapy with statins in acute coronary syndrome (ACS) patients with diabetes mellitus (DM) is not well characterized. METHODS AND RESULTS: We explored this question in data from the Pravastatin or Atorvastatin Evaluation …
AIMS: The impact of intensive lipid lowering therapy with statins in acute coronary syndrome (ACS) patients with diabetes mellitus (D …
REVERSAL and PROVE-IT: are clinically oriented trials really better than "pure" scientific studies?
Cicero AF, Gaddi A. Cicero AF, et al. Int J Cardiol. 2005 Sep 1;103(3):235-7. doi: 10.1016/j.ijcard.2004.07.018. Int J Cardiol. 2005. PMID: 16098383
Recently, two large randomised clinical trials compared the effects of standard and intensive lipid-lowering treatment (Pravastatin 40 mg vs. Atorvastatin 40 mg b.i.d.) on patient prognosis after acute coronary syndromes--the Pravastatin or Atorvastatin Evalu …
Recently, two large randomised clinical trials compared the effects of standard and intensive lipid-lowering treatment (Pravastatin 4 …
Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E; PROVE IT-TIMI 22 Investigators. Ray KK, et al. J Am Coll Cardiol. 2005 Oct 18;46(8):1405-10. doi: 10.1016/j.jacc.2005.03.077. J Am Coll Cardiol. 2005. PMID: 16226162 Free article. Clinical Trial.
BACKGROUND: The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) trial showed that the use of intensive statin therapy improved clinical outcomes over two years in ACS patients ver …
BACKGROUND: The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE …
36 results